|dc.contributor.author||Chao, Chung-Hao H.||en|
|dc.contributor.author||Huang, Yuh-Chin T.||en|
|dc.creator||Chao, Ting-Ting;Wang, Cheng-Yi;Chen, Yen-Lin;Lai, Chih-Cheng;Chang, Fang-Yu;Tsai, Yi-Ting;Chao, Chung-Hao H.;Shiau, Chung-Wai;Huang, Yuh-Chin T.;Yu, Chong-Jen;Chen, Kuen-Feng||en|
|dc.description.abstract||Afatinib has anti-tumor effect in non-small cell lung carcinoma (NSCLC) with epidermal growth factor receptor (EGFR) mutation. We found afatinib can also induce apoptosis in NSCLC cells without EGFR mutation through CIP2A pathway. Four NSCLC cell lines (H358 H441 H460 and A549) were treated with afatinib to determine their sensitivity to afatinib-induced cell death and apoptosis. The effects of CIP2A on afatinib-induced apoptosis were confirmed by overexpression and knockdown of CIP2A expression in the sensitive and resistant cells, respectively. Reduction of Elk-1 binding to the CIP2A promoter and suppression of CIP2A transcription were analyzed. In vivo efficacy of afatinib against H358 and H460 xenografts tumors were also determined in nude mice. Afatinib induced significant cell death and apoptosis in H358 and H441 cells, but not in H460 or A549 cells. The apoptotic effect of afatinib in sensitive cells was associated with downregulation of CIP2A, promotion of PP2A activity and decrease in AKT phosphorylation. Afatinib suppressed CIP2A at the gene transcription level by reducing the promoter binding activity of Elk-1. Clinical samples showed that higher CIP2A expression predicted a poor prognosis and Elk-1 and CIP2A expressions were highly correlated. In conclusion, afatinib induces apoptosis in NSCLC without EGFR mutations through Elk-1/CIP2A/PP2A/AKT pathway.||-|
|dc.relation||Oncotarget, 6(4), 2164-2179||-|
|dc.title||Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A||-|
|Appears in Collections:||臨床醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.